Valeant dealt 'a major setback' as psoriasis dual-drug lotion Duobrii fails to impress FDA

18th June 2018 Uncategorised 0

Besides getting a new name, troubled Valeant is also in desperate need of some regulatory success to rebuild its image. But it’s not going to get it—at least not soon—from psoriasis combo drug Doubrii, which Valeant hoped would collectively generate $1 billion in peak sales before 2023.

More: Valeant dealt 'a major setback' as psoriasis dual-drug lotion Duobrii fails to impress FDA
Source: fierce